Board Change • 23h
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Independent Director A. Sanders was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • May 07
Danaher Corporation announces Quarterly dividend, payable on July 31, 2026 Danaher Corporation announced Quarterly dividend of USD 0.4000 per share payable on July 31, 2026, ex-date on June 26, 2026 and record date on June 26, 2026. Buy Or Sell Opportunity • Mar 29
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to €159. The fair value is estimated to be €199, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 18%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 15% per annum over the same time period. Ankündigung • Mar 26
Danaher Corporation, Annual General Meeting, May 05, 2026 Danaher Corporation, Annual General Meeting, May 05, 2026. Ankündigung • Mar 21
Danaher Corporation to Report Q1, 2026 Results on Apr 21, 2026 Danaher Corporation announced that they will report Q1, 2026 results at 6:00 AM, US Eastern Standard Time on Apr 21, 2026 Ankündigung • Feb 25
Danaher Corporation Announces Quarterly Dividend, Payable on April 24, 2026 Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026. Ankündigung • Feb 11
Danaher Corporation Announces Retirement of Director, Jessica L. Mega, Effective February 5, 2026 Danaher Corporation announced that Jessica L. Mega notified the Board of Directors of her retirement from the Board as of February 5, 2026, due to commitments related to her other professional obligations. Dr. Mega's decision was not the result of any disagreement with Danaher on any matter relating to Danaher's operations, policies or practices. Reported Earnings • Jan 29
Full year 2025 earnings released: EPS: US$5.05 (vs US$5.33 in FY 2024) Full year 2025 results: EPS: US$5.05 (down from US$5.33 in FY 2024). Revenue: US$24.6b (up 2.9% from FY 2024). Net income: US$3.60b (down 7.7% from FY 2024). Profit margin: 15% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Ankündigung • Dec 17
Danaher Corporation to Report Q4, 2025 Results on Jan 28, 2026 Danaher Corporation announced that they will report Q4, 2025 results at 6:00 AM, US Eastern Standard Time on Jan 28, 2026 Declared Dividend • Dec 12
Dividend of US$0.32 announced Shareholders will receive a dividend of US$0.32. Ex-date: 23rd December 2025 Payment date: 30th January 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 25%. Cash payout ratio: 18%. Ankündigung • Dec 10
Danaher Corporation Announces Quarterly Dividend, Payable on January 30, 2026 Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on January 30, 2026 to holders of record on December 26, 2025. Recent Insider Transactions • Nov 27
Co-Founder & Director recently sold €8.1m worth of stock On the 25th of November, Mitchell Rales sold around 41k shares on-market at roughly €199 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €112m. Mitchell has been a net seller over the last 12 months, reducing personal holdings by €203m. Recent Insider Transactions • Nov 14
Co-Founder & Director recently sold €82m worth of stock On the 12th of November, Mitchell Rales sold around 437k shares on-market at roughly €189 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €112m. Mitchell has been a net seller over the last 12 months, reducing personal holdings by €195m. Ankündigung • Nov 08
Danaher Corporation Announces Retirement of John T. Schwieters from Its Board Danaher Corporation announced on November 6, 2025, John T. Schwieters notified the company’s Board of Directors that he has decided not to stand for reelection at the Company’s 2026 annual meeting of shareholders (“2026 Annual Meeting”), and will retire from the Danaher Board as of the 2026 Annual Meeting. Mr. Schwieters’ decision was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The size of the Board will be reduced from thirteen to twelve members as of the time of Mr. Schwieters’ retirement. Recent Insider Transactions • Nov 05
Co-Founder & Director recently sold €112m worth of stock On the 31st of October, Mitchell Rales sold around 600k shares on-market at roughly €187 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Mitchell's only on-market trade for the last 12 months. Reported Earnings • Oct 27
Third quarter 2025 earnings released: EPS: US$1.28 (vs US$1.13 in 3Q 2024) Third quarter 2025 results: EPS: US$1.28 (up from US$1.13 in 3Q 2024). Revenue: US$6.05b (up 4.4% from 3Q 2024). Net income: US$908.0m (up 11% from 3Q 2024). Profit margin: 15% (in line with 3Q 2024). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Ankündigung • Oct 22
Danaher Corporation Provides Revenue Guidance for the Fourth Quarter of 2025 and for the Full Year 2026 Danaher Corporation provided revenue guidance for the fourth quarter of 2025 and for the full year 2026. In the fourth quarter, the company expects core revenue to grow in the low single-digit percent range as it expects market conditions to be largely consistent with what the company saw in third quarter.
For the full year 2026, the company expects core revenue growth in the 3% to 6% range as it is assuming modest recovery across end markets. Ankündigung • Sep 24
Danaher Corporation to Report Q3, 2025 Results on Oct 21, 2025 Danaher Corporation announced that they will report Q3, 2025 results at 6:00 AM, Eastern Standard Time on Oct 21, 2025 Ankündigung • Sep 10
Danaher Announces Quarterly Dividend, Payable on October 31, 2025 Danaher Corporation has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on October 31, 2025 to holders of record on September 26, 2025. Ankündigung • Aug 01
Danaher Corporation Announces Executive Changes Danaher Corporation announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. Prior to joining Danaher, Mr. Leiken served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Dollar Tree Inc., a Fortune 150 company, where he oversaw corporate governance, ethics and compliance, sustainability and regulatory affairs. Prior to that, he held the same role at Diebold Nixdorf Inc., a global technology company, where he also led intellectual property, internal audit and ESG functions. Mr. Leiken's career includes serving as a federal prosecutor in the U.S. Attorney's Office for the Southern District of New York, where he was recognized for superior performance by multiple federal agencies. He has also been a partner at a global law firm, advising Fortune 500 companies and major institutions on complex litigation, corporate strategy and regulatory matters. He holds a J.D., cum laude, from the University of Pennsylvania Law School and a B.A. in Political Science, magna cum laude, from Brandeis University. Ankündigung • Jul 22
Danaher Corporation Announces Chief Financial Officer Changes, Effective February 28 , 2026 Danaher Corporation announced that Matthew Gugino, currently Group Chief Financial Officer of the Company's Life Sciences Innovations Group and Vice President of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's Chief Financial Officer effective February 28th, 2026. Following the transition and consistent with past practice, Mr. McGrew will continue thereafter as an Executive Vice President of the Company, as he begins a gradual transition to retirement, after more than 20 years with Danaher. Mr. McGrew has served as Danaher's CFO since January 2019. He joined Danaher in 2004 as Director, M&A Finance and served in roles of increasing responsibility including Vice President, Investor Relations from 2009 to 2014 and as a Danaher Group CFO from 2012 to 2018. During his tenure as CFO, Danaher meaningfully increased its growth and margin profile, and nearly doubled both its revenue and market capitalization. Mr. Gugino joined Danaher in 2013 as Director, Investor Relations and served as Vice President, Investor Relations from 2014 to 2022. He has served as Vice President of Financial Planning & Analysis since 2019 and additionally as Group Chief Financial Officer in the Company's Life Sciences Innovations Group since 2021. Prior to joining Danaher, he was a Vice President of Equity Research at Barclays and Morgan Stanley, and an Associate at KPMG. He holds a Bachelor of Science degree in Accounting and a Master of Accountancy and Professional Consultancy from Villanova University. Ankündigung • Jun 28
Danaher Corporation(NYSE:DHR) dropped from Russell Top 50 Index Danaher Corporation(NYSE:DHR) dropped from Russell Top 50 Index Ankündigung • Jun 18
Danaher Corporation to Report Q2, 2025 Results on Jul 22, 2025 Danaher Corporation announced that they will report Q2, 2025 results at 6:00 AM, US Eastern Standard Time on Jul 22, 2025 Ankündigung • May 07
Danaher Announces Regular Quarterly Dividend, Payable on July 25, 2025 Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €157, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 17x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €191 per share. Buy Or Sell Opportunity • Apr 05
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 24% to €171. The fair value is estimated to be €220, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.6% over the last 3 years. Earnings per share has declined by 19%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 12% per annum over the same time period. Ankündigung • Mar 28
Danaher Corporation, Annual General Meeting, May 06, 2025 Danaher Corporation, Annual General Meeting, May 06, 2025. 
